HSP90B1 enhanced tumor proliferation and radioresistance in mice (IMAGE)
Caption
(A) The experiment was divided into four groups: Flag-Vector, Flag-HSP90B1, Flag-Vector + IR, and Flag-HSP90B1 + IR. Tumor cells from the different treatment groups were implanted subcutaneously into the mice, and the IR groups received radiotherapy after tumor formation. Tumor volume and mouse weight were regularly monitored, and at the conclusion of the experiment, tumor samples were gathered for further analysis. (B, C) Images of tumors (B) and tumor growth curves (C) from the different treatment groups. (D, E) Upon completion of the experiment, tumor volume (D) and tumor weight (E) were measured, and differences between groups were analyzed. (F, G) Immunohistochemistry was employed to examine HSP90B1, RhoC, and Ki67 expression across the various treatment groups. (H) A model illustrating the function of HSP90B1 in regulating radiotherapy resistance in glioma cells by inhibiting the degradation of RhoC.
Credit
Jiacheng Xu, Yuduo Guo, Jingjing Yang, Guanjie Shang, Weihai Ning, Deshan Liu, Hongwei Zhang, Yongmei Song
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND